-+ 0.00%
-+ 0.00%
-+ 0.00%
Adagene Doses First Patient In First-In-Human Phase 1 Study Of ADG138, Double-Masked HER2×CD3 Bispecific T-Cell Engager Built On IgG1-Based Format And Adagene’s Proprietary Safebody Precision Masking Technology
Share
Listen to the news

First-in-human study will enroll patients with HER2-positive advanced solid tumors

ADG138 design includes proprietary IgG1-based heterodimeric format and SAFEbody® double masking to support prolonged circulation and tumor-selective accumulation and activation

SAN DIEGO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that the first patient has been dosed in a first-in-human Phase 1 study of ADG138, a double-masked HER2×CD3 bispecific T-cell engager built on an IgG1-based format and Adagene’s proprietary SAFEbody® precision masking technology.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending